Golpimec

Golpimec is an oral medication whose active ingredient is fingolimod, a sphingosine‑1‑phosphate (S1P) receptor modulator used in the European market. It is classified as an immunomodulator and disease‑modifying therapy for multiple sclerosis, and it is available by prescription only.

Golpimec is prescribed for patients with relapsing‑remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to slow disease progression.

- Reduces annualized relapse rate in RRMS. - Delays accumulation of disability. - May be used as first‑line or escalation therapy. - Administered orally once daily. - Typically considered for adults with a confirmed diagnosis of RRMS. - May be selected when disease‑modifying therapy is indicated.

Golpimec can cause a range of side effects, some of which are common and others that require prompt medical attention.

Common: - Headache - Upper respiratory tract infection - Diarrhea - Elevated liver enzymes - Fatigue - Nasopharyngitis

Serious: - Bradycardia or other cardiac conduction abnormalities - Severe infections (e.g., herpes zoster) - Macular edema - Liver injury - Progressive multifocal leukoencephalopathy (PML) (rare) - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before starting Golpimec, several safety considerations should be reviewed.

- Contraindicated in pregnancy (Category X) and requires effective contraception. - Baseline cardiac assessment is recommended due to potential bradycardia. - Monitor liver function tests regularly. - Screen for infections, especially varicella‑zoster, before initiation. - Vaccinations should be administered at least 4 weeks prior to therapy. - Caution in patients with a history of macular edema; ophthalmologic exams are advised. - Discontinue if severe adverse reactions occur.

Golpimec may interact with other medicines, influencing its safety and effectiveness.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can increase fingolimod exposure. - Live vaccines during treatment and for at least 2 months after discontinuation. - Other immunosuppressive agents that may heighten infection risk.

Use with caution: - CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce efficacy. - Antihypertensive drugs that could exacerbate bradycardia. - Drugs affecting cardiac conduction (e.g., amiodarone, beta‑blockers). - Medications known to cause macular edema.